Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
24 hedge funds and large institutions have $10.3M invested in Marinus Pharmaceuticals, Inc in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 8 closing their positions.
11% less funds holding
Funds holding: 27 → 24 (-3)
21% less capital invested
Capital invested by funds: $13M → $10.3M (-$2.7M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$570K |
| 2 |
JGC
J. Goldman & Co
New York
|
+$526K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$17.5K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$5.85K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$405K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$114K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$94.6K |
| 4 |
BlackRock
New York
|
-$92.5K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$70.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TDC
26
Thompson Davis & Co
Richmond,
Virginia
| – | -$23K | -3,250 | Closed |
|
|
CGT
27
Capital Guardian Trust
Los Angeles,
California
| – | -$7K | -1,030 | Closed |
|
|
AIM
28
Acrospire Investment Management
Chicago,
Illinois
| – | -$3K | -424 | Closed |
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$459 | -85 | -68% |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$5 | +1 | New |
|
MRNS Hedge Fund Activity: Q2 2017 in Review
24 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q2 2017, worth a combined $10.3M — down 21% from $13M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MRNS and 5 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 3 added.
The largest buyer was Jennison Associates, adding an estimated $570K. The largest seller was Nexthera Capital, cutting an estimated $405K.
- 24 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q2 2017, down from 27 in Q1 2017.
- Funds reported $10.3M of Marinus Pharmaceuticals, Inc stock for Q2 2017, down 21% quarter-over-quarter.
- 5 funds opened new Marinus Pharmaceuticals, Inc positions in Q2 2017 and 8 closed out, a net change of -3 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q2 2017 was Jennison Associates, an estimated $570K added.
- The largest Marinus Pharmaceuticals, Inc seller in Q2 2017 was Nexthera Capital, an estimated $405K sold.
Based on aggregated 13F filings for Q2 2017.